GLP1R and type 2 diabetes mellitus: To date, in this study T2DM patients affected by HFrEF after CRT-d implant were divided randomly in patients receiving GLP1 RA therapy plus conventional hypoglycemic therapy vs. patients under conventional hypoglycemic therapy.